Erasca (ERAS) Revenue & Revenue Breakdown
Erasca Revenue Highlights
00
Erasca Revenue by Period
Erasca Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Erasca generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Erasca Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | - | 100.00% |
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $4.20M | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $5.58M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
Erasca generated - in revenue during Q3 2025, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Erasca Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ARVN | Arvinas | $263.40M | $41.90M |
| IOVA | Iovance Biotherapeutics | $164.07M | $67.45M |
| VALN | Valneva SE | $153.70M | $32.75M |
| CTMX | CytomX Therapeutics | $138.10M | $18.66M |
| MGTX | MeiraGTx | $33.28M | $3.69M |
| CRVS | Corvus Pharmaceuticals | - | - |
| MLTX | MoonLake Immunotherapeutics | - | - |
| ATXS | Astria Therapeutics | - | $706.00K |
| MBX | MBX Biosciences | - | - |
| ERAS | Erasca | - | - |
| AVBP | ArriVent BioPharma | - | - |